Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients

Taispeáin leaganacha eile (1)

We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Wong, K, Gascoyne, D, Brown, P, Soilleux, E, Snell, C, Chen, H, Lyne, L, Lawrie, C, Gascoyne, R, Pedersen, L, Møller, M, Pulford, K, Murphy, D, Green, T, Banham, A
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2014

Míreanna comhchosúla

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
de réir: Wong, K, et al.
Foilsithe / Cruthaithe: (2014)

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
de réir: Wong, K, et al.
Foilsithe / Cruthaithe: (2016)

The significance of FOXP1 in diffuse large B-cell lymphoma
de réir: Gascoyne, D, et al.
Foilsithe / Cruthaithe: (2016)

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
de réir: Brown, P, et al.
Foilsithe / Cruthaithe: (2015)

DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
de réir: Loo, SK, et al.
Foilsithe / Cruthaithe: (2017)

Vitamin D receptor expression in plasmablastic lymphoma and myeloma cells confers susceptibility to vitamin D
de réir: Gascoyne, D, et al.
Foilsithe / Cruthaithe: (2016)

CRISPR/Cas9-mediated Foxp1 silencing restores immune surveillance in an immunocompetent A20 lymphoma model
de réir: Felce, SL, et al.
Foilsithe / Cruthaithe: (2020)

Is FOXP3 expressed in cutaneous T-cell lymphomas?
de réir: Banham, A, et al.
Foilsithe / Cruthaithe: (2008)

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
de réir: Brown, P, et al.
Foilsithe / Cruthaithe: (2016)

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
de réir: Banham, A, et al.
Foilsithe / Cruthaithe: (2005)

The architectural pattern of FOXP3(+) T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
de réir: Farinha, P, et al.
Foilsithe / Cruthaithe: (2006)

The architectural pattern of FOXP3*T cells is an independent predictor of survival in patients with follicular lymphoma (FL)
de réir: Farinha, P, et al.
Foilsithe / Cruthaithe: (2006)

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
de réir: Nyman, H, et al.
Foilsithe / Cruthaithe: (2009)

Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling
de réir: Wong, K, et al.
Foilsithe / Cruthaithe: (2008)

Identification of Huntingtin interacting protein 1 related (HIP1R) as a novel lymphoma autoantigen using antigen array profiling
de réir: Wong, K, et al.
Foilsithe / Cruthaithe: (2009)

The forkhead transcription factor FOXP2 is required for regulation of p21WAF1/CIP1 in 143B osteosarcoma cell growth arrest
de réir: Gascoyne, DM, et al.
Foilsithe / Cruthaithe: (2015)

The NFIL3 transcription factor is preferentially expressed in BCR-independent mature B-cell malignancy
de réir: Gascoyne, D, et al.
Foilsithe / Cruthaithe: (2012)

The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.
de réir: Brown, P, et al.
Foilsithe / Cruthaithe: (2005)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
de réir: Camilleri, E, et al.
Foilsithe / Cruthaithe: (2012)

MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
de réir: Borovecki, A, et al.
Foilsithe / Cruthaithe: (2007)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
de réir: Banham, A, et al.
Foilsithe / Cruthaithe: (2009)

FOXP3 expression in B and T cell lymphomas.
de réir: Roncador, G, et al.
Foilsithe / Cruthaithe: (2005)

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
de réir: Copie-Bergman, C, et al.
Foilsithe / Cruthaithe: (2009)

FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
de réir: Goatly, A, et al.
Foilsithe / Cruthaithe: (2008)

FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control
de réir: Goatly, A, et al.
Foilsithe / Cruthaithe: (2008)

Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species.
de réir: Banham, A, et al.
Foilsithe / Cruthaithe: (2009)

Expression of FOXP2 is up-regulated in lymphoid malignancies
de réir: Campbell, A, et al.
Foilsithe / Cruthaithe: (2009)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
de réir: Barrans, S, et al.
Foilsithe / Cruthaithe: (2004)

Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
de réir: Barrans, S, et al.
Foilsithe / Cruthaithe: (2007)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
de réir: Haralambieva, E, et al.
Foilsithe / Cruthaithe: (2006)

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
de réir: Nyman, H, et al.
Foilsithe / Cruthaithe: (2009)

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
de réir: Nyman, H, et al.
Foilsithe / Cruthaithe: (2008)

FOXP1: a potential therapeutic target in cancer.
de réir: Koon, H, et al.
Foilsithe / Cruthaithe: (2007)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
de réir: Ait-Tahar, K, et al.
Foilsithe / Cruthaithe: (2009)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
de réir: Cooper, C, et al.
Foilsithe / Cruthaithe: (2011)

Strong expression of FOXP1 predicts for poor prognosis within the non-germinal centre subgroup of diffuse large B cell lymphoma
de réir: Barrans, S, et al.
Foilsithe / Cruthaithe: (2005)

Regulation of the mobile genetic element ICEBs1 by a conserved repressor and anti-repressor
de réir: Bose, Baundauna
Foilsithe / Cruthaithe: (2010)

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
de réir: Cooper, C, et al.
Foilsithe / Cruthaithe: (2006)

FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma.
de réir: Roncador, G, et al.
Foilsithe / Cruthaithe: (2005)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
de réir: Ait-Tahar, K, et al.
Foilsithe / Cruthaithe: (2009)